News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation
Cryoballoon (CB)-guided pulmonary vein isolation (PVI) represents a cornerstone in the treatment of atrial fibrillation (AF). Recently, a novel balloon-guided single shot device (POLARx, Boston Scientific) was designed. Our study aimed to compare the efficacy, safety and characteristics of the novel...
Published in: | Journal of Cardiovascular Development and Disease |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
MDPI AG
2022
|
Subjects: | |
Online Access: | https://doi.org/10.3390/jcdd9010016 https://doaj.org/article/cc4163b335c3488e8c3e1922f6464051 |
id |
ftdoajarticles:oai:doaj.org/article:cc4163b335c3488e8c3e1922f6464051 |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:cc4163b335c3488e8c3e1922f6464051 2023-05-15T14:59:18+02:00 News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation Denise Guckel Philipp Lucas Khuraman Isgandarova Mustapha El Hamriti Leonard Bergau Thomas Fink Vanessa Sciacca Guram Imnadze Martin Braun Moneeb Khalaph Georg Nölker Philipp Sommer Christian Sohns 2022-01-01T00:00:00Z https://doi.org/10.3390/jcdd9010016 https://doaj.org/article/cc4163b335c3488e8c3e1922f6464051 EN eng MDPI AG https://www.mdpi.com/2308-3425/9/1/16 https://doaj.org/toc/2308-3425 doi:10.3390/jcdd9010016 2308-3425 https://doaj.org/article/cc4163b335c3488e8c3e1922f6464051 Journal of Cardiovascular Development and Disease, Vol 9, Iss 16, p 16 (2022) atrial fibrillation catheter ablation cryoballoon single-shot ablation devices Diseases of the circulatory (Cardiovascular) system RC666-701 article 2022 ftdoajarticles https://doi.org/10.3390/jcdd9010016 2022-12-31T14:47:37Z Cryoballoon (CB)-guided pulmonary vein isolation (PVI) represents a cornerstone in the treatment of atrial fibrillation (AF). Recently, a novel balloon-guided single shot device (POLARx, Boston Scientific) was designed. Our study aimed to compare the efficacy, safety and characteristics of the novel CB system with the established one (Arctic Front Advance (Pro), AFA, Medtronic). A total number of 596 patients undergoing CB-guided ablation for AF were included. 65 patients (65.0 ± 11.6, 31% female) undergoing PVI with the POLARx were compared to a cohort of 531 consecutive patients (63.0 ± 27.9, 25% female) treated with AFA. Acute PVI was achieved in all patients (n = 596, 100%). Total procedure duration (POLARx 113.3 ± 23.2 min, AFA 100.9 ± 21.3 min; p < 0.001) and fluoroscopy time (POLARx 10.5 ± 5.9 min, AFA 4.8 ± 3.6 min; p < 0.001) were significantly longer in the POLARx group. The POLARx balloon achieved significantly lower nadir temperatures (POLARx −57.7 ± 0.9 °C, AFA −45.1 ± 2.6 °C; p < 0.001) and a significantly higher percentage of pulmonary veins successfully isolated with the first freeze ( p = 0.027 *). One major complication occurred in the POLARx (2%) and three (1%) in the AFA group. Both ablation systems are comparably safe and effective. AF ablation utilizing the POLARx system is associated with longer procedure and fluoroscopy times as well as lower nadir temperatures. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Journal of Cardiovascular Development and Disease 9 1 16 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
atrial fibrillation catheter ablation cryoballoon single-shot ablation devices Diseases of the circulatory (Cardiovascular) system RC666-701 |
spellingShingle |
atrial fibrillation catheter ablation cryoballoon single-shot ablation devices Diseases of the circulatory (Cardiovascular) system RC666-701 Denise Guckel Philipp Lucas Khuraman Isgandarova Mustapha El Hamriti Leonard Bergau Thomas Fink Vanessa Sciacca Guram Imnadze Martin Braun Moneeb Khalaph Georg Nölker Philipp Sommer Christian Sohns News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation |
topic_facet |
atrial fibrillation catheter ablation cryoballoon single-shot ablation devices Diseases of the circulatory (Cardiovascular) system RC666-701 |
description |
Cryoballoon (CB)-guided pulmonary vein isolation (PVI) represents a cornerstone in the treatment of atrial fibrillation (AF). Recently, a novel balloon-guided single shot device (POLARx, Boston Scientific) was designed. Our study aimed to compare the efficacy, safety and characteristics of the novel CB system with the established one (Arctic Front Advance (Pro), AFA, Medtronic). A total number of 596 patients undergoing CB-guided ablation for AF were included. 65 patients (65.0 ± 11.6, 31% female) undergoing PVI with the POLARx were compared to a cohort of 531 consecutive patients (63.0 ± 27.9, 25% female) treated with AFA. Acute PVI was achieved in all patients (n = 596, 100%). Total procedure duration (POLARx 113.3 ± 23.2 min, AFA 100.9 ± 21.3 min; p < 0.001) and fluoroscopy time (POLARx 10.5 ± 5.9 min, AFA 4.8 ± 3.6 min; p < 0.001) were significantly longer in the POLARx group. The POLARx balloon achieved significantly lower nadir temperatures (POLARx −57.7 ± 0.9 °C, AFA −45.1 ± 2.6 °C; p < 0.001) and a significantly higher percentage of pulmonary veins successfully isolated with the first freeze ( p = 0.027 *). One major complication occurred in the POLARx (2%) and three (1%) in the AFA group. Both ablation systems are comparably safe and effective. AF ablation utilizing the POLARx system is associated with longer procedure and fluoroscopy times as well as lower nadir temperatures. |
format |
Article in Journal/Newspaper |
author |
Denise Guckel Philipp Lucas Khuraman Isgandarova Mustapha El Hamriti Leonard Bergau Thomas Fink Vanessa Sciacca Guram Imnadze Martin Braun Moneeb Khalaph Georg Nölker Philipp Sommer Christian Sohns |
author_facet |
Denise Guckel Philipp Lucas Khuraman Isgandarova Mustapha El Hamriti Leonard Bergau Thomas Fink Vanessa Sciacca Guram Imnadze Martin Braun Moneeb Khalaph Georg Nölker Philipp Sommer Christian Sohns |
author_sort |
Denise Guckel |
title |
News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation |
title_short |
News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation |
title_full |
News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation |
title_fullStr |
News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation |
title_full_unstemmed |
News from the Cold Chamber: Clinical Experiences of POLARx versus Arctic Front Advance for Single-Shot Pulmonary Vein Isolation |
title_sort |
news from the cold chamber: clinical experiences of polarx versus arctic front advance for single-shot pulmonary vein isolation |
publisher |
MDPI AG |
publishDate |
2022 |
url |
https://doi.org/10.3390/jcdd9010016 https://doaj.org/article/cc4163b335c3488e8c3e1922f6464051 |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Journal of Cardiovascular Development and Disease, Vol 9, Iss 16, p 16 (2022) |
op_relation |
https://www.mdpi.com/2308-3425/9/1/16 https://doaj.org/toc/2308-3425 doi:10.3390/jcdd9010016 2308-3425 https://doaj.org/article/cc4163b335c3488e8c3e1922f6464051 |
op_doi |
https://doi.org/10.3390/jcdd9010016 |
container_title |
Journal of Cardiovascular Development and Disease |
container_volume |
9 |
container_issue |
1 |
container_start_page |
16 |
_version_ |
1766331406726725632 |